Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma

References

• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 1;372(1):30–39.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019 Oct 17;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015 Jun 18;161(7):1681–1696.
   PubMed Web of Science ®Google Scholar
• Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012 Jul 10;30(20):2522–2529.
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017 Jul 1;28(7):1631–1639.
   PubMed Web of Science ®Google Scholar
• Alberts BJA, Johnson A, Lewis J, et al. An overview of the cell cycle. Molecular biology of the cell. 4th ed. New York: Garland Science; 2002.
   Google Scholar
• Morgan DO. Principles of CDK regulation. Nature. 1995 Mar 9;374(6518):131–134.
   PubMed Web of Science ®Google Scholar
• Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003 Jun;36(3):131–149.
   PubMed Web of Science ®Google Scholar
• Nurse P, Masui Y, Hartwell L. Understanding the cell cycle. Nat Med. 1998 Oct;4(10):1103–1106.
   PubMed Web of Science ®Google Scholar
• Nurse PM. Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep. 2002 Oct-Dec;22(5–6):487–499.
   PubMed Web of Science ®Google Scholar
• Hunt T. Nobel lecture. Protein synthesis, proteolysis, and cell cycle transitions. Biosci Rep. 2002 Oct-Dec;22(5–6):465–486.
   PubMed Web of Science ®Google Scholar
• Pines J. Cyclins: wheels within wheels. Cell Growth Differ. 1991 Jun;2(6):305–310.
   PubMedGoogle Scholar
• Kollmann K, Briand C, Bellutti F, et al. The interplay of CDK4 and CDK6 in melanoma. Oncotarget. 2019 Feb 15;10(14):1346–1359.
   PubMedGoogle Scholar
• Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998 Feb;18(2):753–761.
   PubMed Web of Science ®Google Scholar
• Lees JA, Saito M, Vidal M, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol. 1993 Dec;13(12):7813–7825.
   PubMed Web of Science ®Google Scholar
• Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013 Aug;14(8):518–528.
   PubMed Web of Science ®Google Scholar
• Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994 Jan;8(1):9–22.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163.
   PubMed Web of Science ®Google Scholar
• Reynisdóttir I, Polyak K, Iavarone A, et al. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 1995 Aug 1;9(15):1831–1845.
   PubMed Web of Science ®Google Scholar
• Ertosun MG, Hapil FZ, Osman Nidai O. E2F1 transcription factor and its impact on growth factor and cytokine signaling. Cytokine Growth Factor Rev. 2016 Oct;31:17–25.
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17;353(20):2135–2147.
   PubMed Web of Science ®Google Scholar
• Griewank KG, Scolyer RA, Thompson JF, et al. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst. 2014 Feb;106(2):djt435.
   PubMedGoogle Scholar
• Walker GJ, Flores JF, Glendening JM, et al. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer. 1998 Jun;22(2):157–163.
   PubMed Web of Science ®Google Scholar
• Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol. 1997 Nov;15(11):3301–3312.
   PubMed Web of Science ®Google Scholar
• Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996 Jan;12(1):97–99.
   PubMed Web of Science ®Google Scholar
• Sotillo R, Garcia JF, Ortega S, et al. Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13312–13317.
   PubMed Web of Science ®Google Scholar
• Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016 Apr;45:129–138.
   PubMed Web of Science ®Google Scholar
• Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10557–10561.
   PubMed Web of Science ®Google Scholar
• Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013 Sep 1;19(17):4868–4878.
   PubMed Web of Science ®Google Scholar
• Karim RZ, Li W, Sanki A, et al. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol. 2009 Oct;17(5):361–367.
   PubMed Web of Science ®Google Scholar
• Sanki A, Li W, Colman M, et al. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology. 2007 Dec;39(6):551–557.
   PubMed Web of Science ®Google Scholar
• Eliason MJ, Larson AA, Florell SR, et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol. 2006 Mar;126(3):660–666.
   PubMed Web of Science ®Google Scholar
• Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007 Feb;44(2):99–106.
   PubMed Web of Science ®Google Scholar
• Mahmoud F, Shields B, Makhoul I, et al. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Cancer Biol Ther. 2016 Jun 2;17(6):579–591.
   PubMed Web of Science ®Google Scholar
• Wu A, Wu B, Guo J, et al. Elevated expression of CDK4 in lung cancer. J Transl Med. 2011 Apr 11;9:38.
   PubMed Web of Science ®Google Scholar
• Wagner V, Gil J. Senescence as a therapeutically relevant response to CDK4/6 inhibitors. Oncogene. 2020 Jul;39(29):5165–5176.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Geroconversion: irreversible step to cellular senescence. Cell Cycle. 2014;13(23):3628–3635.
   PubMed Web of Science ®Google Scholar
• Coppé JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008 Dec 2;6(12):2853–2868.
   PubMed Web of Science ®Google Scholar
• Zou X, Ray D, Aziyu A, et al. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 2002 Nov 15;16(22):2923–2934.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Lee EK, Diehl JA. Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4/6. Cancer Res. 2016 May 15;76(10):2990–3002.
   PubMed Web of Science ®Google Scholar
• Damsky W, Micevic G, Meeth K, et al. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell. 2015 Jan 12;27(1):41–56.
   PubMed Web of Science ®Google Scholar
• Coppé JP, Rodier F, Patil CK, et al. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem. 2011 Oct 21;286(42):36396–36403.
   PubMed Web of Science ®Google Scholar
• Guan X, LaPak KM, Hennessey RC, et al. Stromal senescence by prolonged CDK4/6 INHIBITION POTENTIATES TUMOR GROWTH. Mol Cancer Res. 2017 Mar;15(3):237–249.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015 Feb;14(2):130–146.
   PubMed Web of Science ®Google Scholar
• Xu W, McArthur G. Cell cycle regulation and melanoma. Curr Oncol Rep. 2016 Jun;18(6):34.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153–166.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001 Dec;1(3):222–231.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Palbociclib: first global approval. Drugs. 2015 Apr;75(5):543–551.
   PubMed Web of Science ®Google Scholar
• Lee B, McArthur GA. CDK4 inhibitors an emerging strategy for the treatment of melanoma. Melanoma Manag. 2015 Aug;2(3):255–266.
   PubMed Web of Science ®Google Scholar
• Chohan TA, Qayyum A, Rehman K, et al. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers. Biomed Pharmacother. 2018;107:1326–1341.
   PubMed Web of Science ®Google Scholar
• Whittaker SR, Mallinger A, Workman P, et al. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017;173:83–105.
   PubMed Web of Science ®Google Scholar
• Sedlacek H, Czech J, Naik R, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol. 1996 Dec;9(6):1143–1168.
   PubMed Web of Science ®Google Scholar
• Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6(3):918–925.
   PubMed Web of Science ®Google Scholar
• Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996 Jul 1;56(13):2973–2978.
   PubMed Web of Science ®Google Scholar
• Blum KA, Ruppert AS, Woyach JA, et al. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia. 2011 Sep;25(9):1444–1451.
   PubMed Web of Science ®Google Scholar
• Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010 Aug;9(8):2344–2353.
   PubMed Web of Science ®Google Scholar
• Stephenson JJ, Nemunaitis J, Joy AA, et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer. 2014 Feb;83(2):219–223.
   PubMed Web of Science ®Google Scholar
• Efficacy study of P276-00 in subjects of malignant melanoma positive for cyclin D1 expression. [cited 2020 May 31]. Available from: https://ClinicalTrials.gov/show/NCT00835419.
   Google Scholar
• AT7519M in treating patients with advanced or metastatic solid tumors or refractory non-Hodgkin’s Lymphoma. [cited 2020 May 31]. Available from: https://ClinicalTrials.gov/show/NCT00390117.
   Google Scholar
• Phase Ii trial of the cyclin-depedent kinase inhibitor Pd 0332991 in patients with cancer. [cited 2020 May 31]. Available from: https://ClinicalTrials.gov/show/NCT01037790.
   Google Scholar
• A study of LY2835219 in Japanese participants with advanced cancer. [cited 2020 May 31]. Available from: https://ClinicalTrials.gov/show/NCT02014129.
   Google Scholar
• Mahoney E, Byrd JC, Johnson AJ. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Autophagy. 2013 Mar;9(3):434–435.
   PubMed Web of Science ®Google Scholar
• Koboldt D, Fulton R, McLellan M, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from Discovery to Therapy. Cancer Discov. 2016 Apr;6(4):353–367.
   PubMed Web of Science ®Google Scholar
• O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016 Jul;13(7):417–430.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471–475.
   PubMed Web of Science ®Google Scholar
• Yadav V, Burke TF, Huber L, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253–2263.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Diehl JA. CDK4/6 inhibitor: from quiescence to senescence. Oncoscience. 2015;2(11):896–897.
   PubMedGoogle Scholar
• AbuHammad S, Cullinane C, Martin C, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990–18000.
   PubMed Web of Science ®Google Scholar
• Syed YY. Ribociclib: first Global Approval. Drugs. 2017 May;77(7):799–807.
   PubMed Web of Science ®Google Scholar
• Kim ES. Abemaciclib: first global approval. Drugs. 2017 Dec;77(18):2063–2070.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427–1438.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res. 2017 Jul 1;23(13):3251–3262.
   PubMed Web of Science ®Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825–837.
   PubMed Web of Science ®Google Scholar
• Wang LM, Ren DM. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem. 2010;Oct;10(11):1058–1070.
   PubMed Web of Science ®Google Scholar
• Burdette-Radoux S, Tozer RG, Lohmann RC, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs. 2004 Aug;22(3):315–322.
   PubMed Web of Science ®Google Scholar
• Bible KC, Lensing JL, Nelson SA, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res. 2005;11(16):5935.
   PubMed Web of Science ®Google Scholar
• Bahleda R, Grilley-Olson JE, Govindan R, et al. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun;116(12):1505–1512.
   PubMed Web of Science ®Google Scholar
• Nemunaitis JJ, Small KA, Kirschmeier P, et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med. 2013;11:259.
   PubMed Web of Science ®Google Scholar
• Dinaciclib in treating patients with stage III-IV melanoma. [cited 2020 May 31]. Available from: https://ClinicalTrials.gov/show/NCT01026324.
   Google Scholar
• Lao CD, Moon J, Fruehauf JP, et al. SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. J clin oncol. 2012 May 20;30(15_suppl):8521.
   Google Scholar
• Gupta S, Jain MM, Maru A, et al. A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. J clin oncol. 2012 May 20;30(15_suppl):3011.
   Web of Science ®Google Scholar
• Study of an oral cdk inhibitor administered with an oral BRAF inhibitor in patients with advanced or inoperable malignant melanoma with BRAF mutation. [cited 2020 May 31]. Available from: https://ClinicalTrials.gov/show/NCT01841463.
   Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012 Jan;18(2):568–576.
   PubMed Web of Science ®Google Scholar
• Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016 Dec;22(23):5696–5705.
   PubMed Web of Science ®Google Scholar
• Nguyen LV, Searle K, Jerzak KJ. Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer. Oncotarget. 2019 Oct;10(59):6317–6322.
   PubMedGoogle Scholar
• Shapiro G, Rosen LS, Tolcher AW, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J clin oncol. 2013 May 20;31(15_suppl):2500.
   PubMedGoogle Scholar
• Tolaney SM, Sahebjam S, Le Rhun E, et al. Abstract P1-19-01: A phase 2 study of abemaciclib in patients with leptomeningeal metastases secondary to HR+, HER2- breast cancer. Cancer Res. 2019;79(4Supplement):P1-19-01.
   Google Scholar
• Taylor M, Sosman J, Gonzalez R, et al. Phase Ib/Ii study of Lee011 (Cdk4/6 inhibitor) and Lgx818 (Braf inhibitor) in Braf-mutant melanoma. Ann Oncol. 2014;25:Iv374.
   Web of Science ®Google Scholar
• Sullivan RJ, Amaria RN, Lawrence DP, et al. Abstract PR06: phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors. Mol Cancer Ther. 2015;14(12 Supplement 2):PR06.
   Google Scholar
• Schuler MH, Ascierto PA, FYFL DV, et al. Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: safety, efficacy, and recommended phase 2 dose (RP2D). J clin oncol. 2017 May 20;35(15_suppl):9519.
   Google Scholar
• Ascierto PA, Bechter O, Wolter P, et al. A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. J clin oncol. 2017 May 20;35(15_suppl):9518.
   Google Scholar
• Teh JLF, Aplin AE. Arrested developments: CDK4/6 inhibitor resistance and alterations in the tumor immune microenvironment. Clin Cancer Res. 2019 Feb 1; 25(3):921–927.
   PubMed Web of Science ®Google Scholar
• Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018 Mar 13;22(11):2978–2994.
   PubMed Web of Science ®Google Scholar
• A study of anti-PD-L1 checkpoint antibody (LY3300054) alone and in combination in participants with advanced refractory solid tumors. [cited 2020 May 31]. Available from: https://ClinicalTrials.gov/show/NCT02791334.
   Google Scholar
• Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007 Jan 15;109(2):399–404.
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Witkiewicz AK. The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer. 2017 Jan;3(1):39–55.
   PubMed Web of Science ®Google Scholar
• Bruyère C, Meijer L. Targeting cyclin-dependent kinases in anti-neoplastic therapy. Curr Opin Cell Biol. 2013 Dec;25(6):772–779.
   PubMed Web of Science ®Google Scholar
• Dean JL, Thangavel C, McClendon AK, et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010 Jul 15;29(28):4018–4032.
   PubMed Web of Science ®Google Scholar
• Biomarkers/Rb1: my cancer genome; 2017. [cited 2020 Sep 17]. Available from: https://www.mycancergenome.org/content/gene/rb1/
   Google Scholar
• Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014 Jul;27(4):590–600.
   PubMed Web of Science ®Google Scholar
• LaPak KM, Burd CE. The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res. 2014 Feb;12(2):167–183.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Höiom V, Tuominen R, et al. Germline CDKN2A mutation status and survival in familial melanoma cases. J Natl Cancer Inst. 2016 Nov;108(11). DOI: 10.1093/jnci/djw135.
   PubMedGoogle Scholar
• Romano G, Chen P-L, Song P, et al. A preexisting rare PIK3CA E545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discov. 2018;8(5):556.
   PubMed Web of Science ®Google Scholar